Pharmaceuticals 2013, 6(5), 681-688; doi:10.3390/ph6050681

Evolution of Biologics Screening Technologies

MedImmune Ltd, Milstein Building, Granta Park, Cambridge CB21 6GH, UK
* Author to whom correspondence should be addressed.
Received: 5 February 2013; in revised form: 23 April 2013 / Accepted: 8 May 2013 / Published: 14 May 2013
(This article belongs to the Special Issue Biologics)
PDF Full-text Download PDF Full-Text [134 KB, uploaded 14 May 2013 12:18 CEST]
Abstract: Screening for biologics, in particular antibody drugs, has evolved significantly over the last 20 years. Initially, the screening processes and technologies from many years experience with small molecules were adopted and modified to suit the needs of biologics discovery. Since then, antibody drug discovery has matured significantly and is today investing earlier in new technologies that commercial suppliers are now developing specifically to meet the growing needs of large molecule screening. Here, we review the evolution of screening and automation technologies employed in antibody discovery and highlight the benefits that these changes have brought.
Keywords: high throughput screening; assay technologies; therapeutic antibodies

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Cariuk, P.; Gardener, M.J.; Vaughan, T.J. Evolution of Biologics Screening Technologies. Pharmaceuticals 2013, 6, 681-688.

AMA Style

Cariuk P, Gardener MJ, Vaughan TJ. Evolution of Biologics Screening Technologies. Pharmaceuticals. 2013; 6(5):681-688.

Chicago/Turabian Style

Cariuk, Peter; Gardener, Matthew J.; Vaughan, Tristan J. 2013. "Evolution of Biologics Screening Technologies." Pharmaceuticals 6, no. 5: 681-688.

Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert